ProCE Banner Activity

First-in-Human Phase I Trial of AMG 420, a BiTE Construct Binding to BCMA x CD3, in Heavily Pretreated Patients With Multiple Myeloma

Slideset Download
Conference Coverage
The BiTE AMG 420 was associated with a high response rate, including patients achieving MRD-negative stringent CR, at study MTD.

Released: December 06, 2018

Expiration: December 05, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology